On this episode of Biotalk, Locust Walk welcomes Jason Kelly, co–Founder and CEO of Ginkgo Bioworks, to the podcast. Ginkgo specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology. In short, Ginkgo provides a wide swath of capabilities to help companies across therapeutics, vaccines, agriculture, nutrition, wellness and other areas to accelerate and advance their own development. Jason discusses what spurred Ginkgo’s interest in biotech, the company’s atypical business model and consideration as a CRO, and how the biotech market downturn has impacted Ginkgo’s business in general. Locust Walk is happy to speak with you further if you have any questions about this episode or if we can be helpful to guide your organization through the current market environment. Timestamps: 1:23: What attracted you to our industry and what made you want to become a biotech entrepreneur? 3:10: While in graduate school at MIT, you founded the company OpenWetWare.org, which is intended to help

0 Comments Sort By